Current Challenges in Non-Invasive Insulin Drug Delivery System:  A Review by Harak, Komal Vilas et al.
Harak et al                                                                                                          Journal of Drug Delivery & Therapeutics. 2019; 9(3-s):982-988 
 ISSN: 2250-1177                                                                                 [982]                                                                                     CODEN (USA): JDDTAO 
Available online on 15.06.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                         Review Article 
Current Challenges in Non-Invasive Insulin Drug Delivery System:  A Review 
Komal V. Harak*1, P.B. Patil1, R.B. Saudhagar2 
1 Department of Pharmaceutics, R. G. Sapkal College of pharmacy, Anjaneri, Nashik- 422213, Maharashtra, India 
2 Department of Quality Assurance Techniques , R. G. Sapkal college of pharmacy, Anjaneri, Nashik- 422213, Maharashtra, India. 
 
ABSTRACT 
The Frederick Banting and Charles Best extracted insulin from bovine pancreas in 1922, who received the Nobel prize for their  contribution in 
the medical field with Johan McLeod, The gastrointestinal tract (GIT) is the route of choice for the administration of most drugs, regardless of 
their molecular structure or weight and administration of insulin exogenously via subcutaneous route which mimic the pancreatic insulin 
secretion, for In todays era, insulin delivery by noninvasive route is an area of current interest in diabetes mellitus treatment by parenteral 
route for type-I and type-II diabetes mellitus , while noninvasive therapy through oral delivery is greatly desired, there are challenges that 
include the low bioavailability due to the rapid enzymatic degradation in the stomach. This review article patent that provides the novel 
approaches for noninvasive insulin drug delivery system to the bloodstream through the go tract.  
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Diabetes mellitus is a chronic condition associated with 
abnormal high blood sugar (glucose) levels. Normally 
diabetes is of two types. Type I DM/Insulin Dependent 
Diabetes Mellitus (IDDM) is due to body’s inability to 
produce insulin due to the autoimmune destruction of the 
beta cells in the pancreas8. Type 2 diabetes mellitus, in 
which peripheral cells become resistant to the insulin 
secreted by the patients body. Selective individuals with 
type 2 diabetes mellitus or those at a later stage of type 2 
diabetes mellitus require exogenous insulin supply. the 
hormonal changes during pregnancy causes glucose 
intolerance in some women. This is caused due to the 
resistance of peripheral cells to insulin. This condition is 
called as gestational diabetes mellitus and this condition 
usually reverses after delivery. In a few cases this condition 
persists for lifetime. Insulin therapy, which is the exogenous 
supply of insulin is highly effective in regulating blood 
glucose level in diabetes patients7. Type I diabetes 
is a noninsulin dependent diabetes mellitus (NIDDM) and re
sults in an  insulin resistance‐ a condition in which body cells
 fail to use insulin properly, sometimes combined with reduc
ed amount of insulin secretion. When insulin was discovered
, it was first delivered by parenteral route. Insulin is delivere
d to diabetic patients exclusively via the subcutaneous route.
 The usual duration of action is relatively short; i.e., 48 hrs an
d therefore daily 2 to 4 injections are required for proper co
ntrol of severe diabetic condition. The parenteral route is sat
isfactory in terms of efficacy. However, it may result to some 
severe adverse conditions like, a peripheral hyperinsulinemi
a, a smooth muscle cell proliferation, and a diabetic micro an
d macro angiopathy 3. In addition, the burden of daily injecti
ons, physiological stress, pain, inconvenience, cost, and the l
ocalized deposition of insulin leads to a local hypertrophy an
d fat deposition at the injection sites 4. Therefore, now a day 
there has been more focus on noninvasive route of insulin de
livery. In 1996 AD, the FDA approved the first recombinant 
DNA human insulin analogue, lispro (Humalog). In 2001 AD, 
FDA approved Cygnus’ firstgeneration model of the GlucoWa
tch Biographer for use by adults ‐ the first frequent, automati
c and noninvasive glucose monitor. Research approaches for 
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Table 1: It shows research approaches for noninvasive insulin  delivery 
Devices Method of delivery 
Oral route Uptake of insulin occurring, within the GI tract or buccal mucosa. 
Pulmonary Uptake of insulin occurring in the highly vascularized alveoli of the lung 
Intranasal Use of nasal membranes as absorptive surface for insulin 
Iontophoresis Transdermal delivery of insulin by direct electrical current 
 Ultrasound Process by which sound waves increases by several fold the permeability of human skin to 
macromolecules. 
 
Insulin is a hormone secreted from the β cells of the islets of 
langerhans of pancreas. Insulin is a protein consisting of two 
polypeptide chains, one of 21 amino acid residues and the 
other of 30, joined by two disulfide bridges2. Insulin therapy 
is effective at lowering blood glucose in patients with 
diabetes. Insulin is a key player in the control of 
hyperglycaemia for type 1 diabetes patients and in selective 
patients with type 2 diabetes mellitus of insulin was 
considered as the most successful step in the history of 
diabetes treatment. It was isolated in 1921 and clinically 
used in 192212. The major achievements in this area include 
the synthesis of human insulin analogues by recombinant 
DNA technology 11. Insulin which is very close to human 
insulin is porcine insulin. Currently available forms of insulin 
delivery include insulin syringes, insulin infusion pumps, jet 
injectors and pens 11. Subcutaneous route is the most 
commonly used route of administration of insulin. The main 
drawback of these methods is of invasive nature and 
generally in type I diabetes; a patient should take insulin two 
to three times daily and also may be taken in the form of 
multiple injections. Due to this there is a chance of develop 
hypoglycaemia and cases of hypoglycaemia are observing 
very often. In order to decrease the suffering of patient, new 
ways of administration are developed such as supersonic 
injectors, infusion pumps, sharp needles, and pens 13. But 
they are also of invasive type and in turn develop a problem 
of patient compliance, medication adherence and patient 
inconvenience in administering insulin. So, there is a need of 
developing alternative methods of administration and this 
leads to the development of non-invasive methods of insulin 
administration in order to increase the patient compliance, 
medication adherence etc. Generally the route of 
administration is said to be succeeded when its ability to 
increase effectiveness and lowering the blood glucose levels 
and finally reducing the diabetic complications 13.This 
review discuss about the recent developments in the non-
invasive routes of administration of insulin for diabetes 
mellitus8. 
2. NON-INVASIVE DRUG DELIVERY SYSTEM: 
2.1. Oral insulin: 
It is very challenging for the formulators to deliver a peptide 
like insulin via oral route (Saffran et al., 1997; Jung et 
al.,2000; Soppimath et al., 2001; Lambkin and Pinilla, 2002; 
Shen,2003; Hamman et al., 2005; Cui et al., 2006; Mahkam et 
al., 2006;Qian et al., 2006; des Rieux et al., 2006; Liu et al., 
2006; Sarmentoet al., 2007; Simon et al., 2007), especially if 
it is particular to deliver the peptide  physiologically to liver 
through hepatic portal circulation, which will mimic the 
endogenously secreted insulin by beta cells of pancreas 
(Owens et al,. 2003)2.since insulin is large molecular peptide,  
it is the gastrointestinal tract (GI). Proteolytic enzymes like 
pepsin, trypsin, chymotrypsin and carboxypeptidae, which 
are located in the stomach and small intestinal lumen. These 
proteolytic enzymes are responsible for about 20% degradat
ion of ingested proteins. The remaining of the degradation 
occurs at the brush‐border membrane (by various 
peptidases) or within the enterocytes of the intestinal tract3. 
It is also affected by chemical and enzymatic degradation 
when it enters into the gastro intestinal tract. Highly acidic 
conditions will also accelerate the breaking of di sulfide 
bonds between the chains of insulin molecule which will 
lead to the chemical degradation of the molecule.( 
Gowthamarjan et al,.2003.)  Insulin is also inactivated due to 
the enzymes like pepsin trypsin and chymotrypsin that are 
secreted in various parts of gastro intestinal tract and hence 
will decrease the bioavailability of the drug. (Schilling and 
Mitra, 1991; Saffran et al., 1997; Jung et al., 2000; Soppimath 
et al., 2001; Lambkin and Pinilla, 2002; Shen, 2003; Calceti et 
al., 2004; Hamman et al., 2005; Cui et al., 2006; Mahkam et 
al., 2006)2. To overcome these problems regarding the ora 
linsulin delivery three approaches could be possible. By 
changing the following:  
(i) physicochemical properties of the insulin, for example, 
lipophilicity; 
(ii) crosslinkingwithmacromolecules;  
(iii)  Use of carrier systems5. 
2.2. Liposomes: 
Liposomes are defined as multilamellar, concentric bilayered 
vesicles in which aqueous volume is entirely enclosed by a 
membranous lipid bilayer composed of   natural and 
synthetic phospholipids.  Liposomes can be used to target 
the drug to liver spleen and bone marrow. Liposomes can be 
used for oral delivery of peptides (Spangler et al,. 1990, 
Katayama et al,.2003,Takeuchi et al., 1996; Kim et al., 1999; 
Iwanaga et al., 1999; Kisel et al., 2001; Wu et al., 2004),  if 
they are prevented from degradation in git by bile 
salts.Resistance to bile salts can be achieved by coating the 
surface of liposomes with PEG or mucin.Hence,surface 
coated liposomes of insulin will have greater stability in 
gastro intestinal tract2. The liposomes are generally unstable 
and thus need to be lyophilized for long-term storage. 
Insulin can be protected from enzymatic attack inside the 
GIT by preparing insulin in the form of liposomes. SDG, Inc. 
(an Ohio Corporation) [29] describes a method of preparing 
orally bioavailable insulin formulations of variously sized 
liposome constructs, such as liposome fragments, lipid 
particles comprising insulin, gelatin and targeting agents 
such as biotin. Fan [30] describes a process of lyophilization 
of insulin liposome powder4. 
2.3. Nanoparticles: 
Nanoparticles are defined as the submicron particles having 
their diameter about 100 nanometer and less.They are used 
as carriers for the oral delivery of peptides like insulin [ 
Damge et al,. 1998] as they are highly stable, feasible for the 
incorporation of many hydrophilic and hydrophobic 
substances, and can release the drug in controlled rate from 
the polymeric matrix and hence increase the bioavailability 
of the drug in the desired site of action. They are synthesized 
using several biodegradable and biocompatible polymers. 
These polymers may be natural like albumin and gelatin or 
synthetic like polyacrylic acid polymers and polylactides. 
Drug is released from the polymeric matrix either by 
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diffusion or the degradation of the matrix.Insulin loaded 
nanoparticles are taken by the peyer’s patches of the 
intestine2. Among these chitosan has a good permeation 
property. In a diabetic rat model nanoparticle with chitosan 
significantly reduces the blood glucose level. Emulsions or 
double emulsion technique, solvent evaporation, or spray 
drying are the presently available methods of preparation of 
these devices. Some factors should be optimized during 
preparation of these devices like release rates and 
encapsulation efficiency to improve their therapeutic 
efficacy. Insulin delivery from oral delivery devices is a 
better approach to overcome the frequent administration of 
subcutaneous injections of insulin. Polymeric devices have 
been widely used for oral insulin delivery through 
hydrogels, nanoparticles, or microparticles8. Prustyetal 
prepared the nanoparticles incorporated with insulin by the 
complex coacervation method. They have been studied 
antidiabetic activity of orally administered insulinin 
rats.These nanoparticles have been evaluated for 
entrapment efficiency, particle size, and in vitro release 
studies, in vivo pharmacological studies, pharmacokinetic 
evaluation, and biochemical parameters. Insulin present in 
serum has also been determined by the use of human insulin 
ELISA kit. Biochemical parameters like creatinine and 
protein levels in the serum were estimated by 
spectrophotometry. Particle size of nanoparticles loaded 
with insulin was observed as 551.67nm ± 45.5 and it was 
determined by scanning electronmicroscopy (SEM). Loading 
efficiency of nanoparticles containing insulin was found 
highest for 50IU/mL insulin loaded nanoparticles and lowest 
for 51IU/mL insulin loaded nanoparticles. Korsmeyer’s 
equation was used in in-vitro studies for determination of 
drug release pattern.There lease of kinetics was found to be 
0.18. In vivo antidiabetic studies showed the significant 
reduction of serum glucose level5. Najafzadeh et al. 
evaluated efficacy of formulation of insulin having polar and 
nonpolar ingredients which has been administered by oral 
route. They concluded that novel excipients used in 
formulation prevent the degradation of insulin from gastric 
enzymes. This formulation significantly reduces the 
concentration of glucose in blood plasma in healthy and 
diabetic rats8.   
2.4. Microspheres: 
Microspheres are solid spherical particles with a size range f
rom 1 to 600 mm and are prepared by double emulsion solv
ent evaporation technique. The microspheres are prepared u
sing natural biodegradable polymers (gelatin or albumin) or 
synthetic polymers (polylactic or polyglycolic acid). In emuls
ion, the dispersed phase consists of droplets of polymerdrug 
solution and they are linked by entrapment, ionic or covalent
 bonding. Microspheres can be prepared either by incorporat
ing the drug in a microcapsule2.These microspheres aid in 
the protection of proteins by preventing them to interact 
with any substance till the complete degradation of the 
polymer, and hence reducing the contact with solutions 
which will degrade the proteins. The micro particles can be 
prepared by coacervation process regulating temperature 
conditions.Insulin can be imbibed into these microparticles 
by diffusion loading. Micro particles of mucin and sodium 
alginate which  are loaded with insulin(Philip F. Builders et 
al,. 2008) and  poly(fumaric-cosebacic) anhydride 
microspheres loaded with insulin(Stacia Furtado et al,.2007) 
showed to be effective as oral insulin delivery3. 
2.5. Niosomes:   
A niosome is a non-active surfactant containing liposome. 
They is very similar to liposomes in structure except they 
contain surfactant which will enhance the stability f the drug 
delivery system. They contain non-ionic surfactant 
belonging to the class of the alkyl or dialkyl polyglycerol 
ether and cholesterol with subsequent hydration in aqueous 
media. They can improve the thepapeutic effect of peptides 
by reducing the clearance time from systemic circulation, 
increased bioavailability2. Recombinant human insulin can 
be delivered by using niosomal formulations7. 
2.6. Hydrogels:   
Hydrogels (Kahyap.,et al 2005), are the colloidal drug 
delivery systems in which drug is dispersed in aqueous 
medium.These are multicomponent systems  which contain 
a threedimensional network of polymer chains and water is 
used as a dispersion medium to fill the spaces between these 
macro molecules2.Hydrogels have been of considerable 
interest for developing self-regulated drug delivery system 
in which a reversible gel-sol transformation controls the 
delivery of solutes as a function of glucose in its 
surroundings. Hydrogels can be made to undergo sol-gel 
transition by various stimuli such as pH and temperature. In 
the hydrated state, they have a mechanical behavior and 
water content similar to soft tissue and as a result they 
exhibit excellent biocompatibility Parket al developed 
glucose-sensitive hydrogels by mixing glucose-containing 
polymers and Poly Ethylene Glycolated(PEG) concanavalin 
A(Con A). Glucose was incorporated into the polymer 
backbone by copolymerization of allyl glucose with co-
monomers, such as 3-sulfopropylacrylate, potassium salt 
(SPAK), N-vinyl pyrrolidone (VP) and acrylamide (AM). The 
authors examined different types of insulin delivery 
systems; diffusion-controlled reservoir, diffusion-controlled 
matrix and erosion-controlled matrix systems. They 
observed that, onset of insulin release in the in vitro studies 
showed a time lag of 30 min from the addition of glucose and 
the insulin release took 2 h to stop on completed removal of 
glucose6. Hydrogels significantly enhance oral absorption of 
insulin with notable hypoglycaemic effect7.  
3. MORDERN INSULIN DRUG DELIVERY SYSTEM 
3.1. Inhaled delivery of insulin: 
Generally lungs are having a larger surface area 
(approximate of about 100 square metres) and acts as an 
ideal target for insulin delivery 3. The first attempt to deliver 
insulin by inhalation was made more than half century ago 4. 
Clinical experience has shown that inhaled insulin has the 
potential to be an effective treatment in patients with 
diabetes, with particular utility in the treatment of 
postprandial hyperglycaemia 5,6. In this mode of 
administration the drug has a relatively faster onset of 
action than subcutaneous route. Inhaled insulin has longer 
glucose lowering activity 7. Generally insulin inhalers work 
as asthma inhalers. These products are generally available in 
two forms as dry powder formulations and solutions 4. Each 
of these formulations is prepared basing on regular human 
insulin 8. Exubera was the first inhaled insulin preparation 
available. It was delivered with an aerosol devise called 
exubera inhaler. Nebulizers, metered dose inhalers and 
aqueous mist inhalers are being investigated. Inhalation is 
an excellent mode for delivering pre-meal time insulin. It can 
be used for delivering fast acting insulin only. It is less 
effective in smokers and those with pulmonary diseases. The 
incidence of hypoglycaemia is also increased with this 
route2,3,6. 
3.2. Buccal delivery of insulin: 
These are the drug delivery systems in which drug are 
administered over the buccal mucosa lining the inner cheek 
and upper gingivae. This route promises to be potential 
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route for the delivery of large hydrophilic molecules like 
proteins and peptides like insulin because this route will 
prevent first pass metabolism, prevent the drug being 
degraded by gastric p H and enzymes, rapid absorption by 
jugular veins, and finally good patient compliance (Sudhakar 
et al,.2006). Several water soluble polymers are added to 
impart adhesive nature to the mucous membrane which will 
increase the site specific drug absorption. Increased 
bioavailability was observed when insulin was administered 
along with absorption enhancers and mucoadhesives.  It was 
found that buccal administration of insulin when formulated 
along with fatty acids like oleic acid, eicosapentaenoic acid 
and docosahexaenoic acid showed sustained hypoglycaemic 
effect in rats. (Morishita et al,. 2001). A significant 
hypoglycaemic effect was observed when insulin was 
administered in the form of muco adhesive polymeric 
nanoparticles through buccal route in diabetic rats and 
rabbits (Venugopalan et al,. 2001)4. One of the disadvantage 
associate the buccal route is low bioavailability which can be 
enhance by the used various permeation absorption 
enhancers like polysorbate 80, sorbitol and 
phosphatidylcholine. A   buccal insulin delivery is under clini
cal development by Generex and Lilly under the names of Or
alyn in Europe and Oralgen in the USA.  Administration is si
milar to an angina spray; with an aerosol (RapidMist®) deliv
ering a fine spray directly onto the buccal mucosa4.OrallynT
M is human regular insulin in a proprietary liquid formulatio
n utilizing surfactants, absorption enhancers, and other GRA
S ingredients in very low quantities. It is delivered to the buc
cal mucosa using a spray device similar to that used in asthm
a. RapidMist™ device is designed to the liquid formulation in
to the oral cavity as a fastmoving and a fineparticle aqueous 
spray. 
The mixed micelles containing the insulin molecules transve
rse the superficial layers of oropharyngeal mucosa and with 
the aid of absorption enhancers, insulin is rapidly absorbed i
nto the blood. Bernstein, G. has suggested the insulin 
delivery by the buccal route in diabetes mellitus in large 
number of patient, particularly in type 2 dibetes mellitus 3. 
In the buccal mucosa the blood supply in reticulated veins is 
very high, so absorption will be also high and this route 
prevents hepatic first pass metabolism. Delivery by inhaler 
containing high pressure droplets of insulin to the back of 
the throat is beneficial. Due to low permeability of buccal 
mucosa more puffs are required for optimum drug delivery 
8,5. 
3.3. Mouth spray: 
Mouth sprays deliver insulin through an aerosol spray and 
hence, they differ from inhalers. In mouth sprays, the insulin 
is absorbed through the inside of cheeks and in the back of 
mouth instead of lungs. Two forms of mouth spray (Rapid 
Mist/Oralin) are being developed by Generex Biotechnology. 
One of the forms is fast-acting whereas, another one covers 
the basal rate of insulin (the basal rate is the amount of 
insulin required throughout the day to keep blood sugars 
stable). (ARIDA AI et al., 2008) 9. The patient does not inhale 
with the buccal spray device as the formulation is delivered 
as fine spray onto the buccal mucosa as shown in the. Rapid 
absorption into the bloodstream is allowed with high-speed 
spray. Inhaled insulin formulation shows the risks to lung 
tissue, this can be avoided as the drug gets deposited onto 
the buccal mucosa10. 
3.4. Pills: 
The concept of delivering insulin by mouth ("peroral" 
delivery) for absorption across the intestinal wall into the 
portal vein has long been regarded as a difficult challenge, 
but of substantial clinical and commercial potential. 
Presently, the biggest challenge with insulin pills is posed by 
the human digestive system. Either the gastrointestinal tract 
breaks the insulin down or the insulin passes out intact 
because it is unable to pass through the gastrointestinal 
membrane9. Controlling postprandial glycaemia requires 
several daily injections of insulin. Treatment using insulin 
through subcutaneous or other parenteral route results in 
peripheral hyperinsulinaemia, this may also include 
coronary artery disease, hypertension, dyslipidemia and 
weight gain along with the risk of hypoglycaemia10. 
3.5. Transdermal delivery of insulin: 
Transdermal delivery of insulin is an alternative to the subcu
taneous injection of insulin in diabetic patients. Apart from b
eing a conventional painless procedure, it can potentially ma
intain a long lasting effect by producing steady blood insulin 
levels over a long period of time. During recent years, variou
s experimental methodologies have been developed for facili
tating transdermal delivery of insulin A chemical 
enhancers based on biphasic lipid system or flexible lecithin
vesicles containing insulin showed good hypoglycemic effect 
in experimental animals5,6. An additional approach to 
facilitate the transdermal delivery of insulin included 
altering skin characteristics by physical tools such as 
iontophoresis, sonophoresis, electroporation and 
photomechanical treatment 2,6. Insulin has a tendency to 
form dimers and hexamers in pharmacological 
compositions, which are considered to be too large for 
transdermal delivery3. The entrapment efficiencies of 
conventional and flexible vesicles were 35% and 81%, 
respectively. When flexible vesicles were non-occlusively 
applied to the abdominal skin of mice at a dose of 0.90 
IU/cm2, an in vivo hypoglycemic study showed a percentage 
decrease in blood glucose of 21.42%± 10.19% at 1 h, which 
reached 61.48%±8.97%at 5 h and was still greater than 50% 
at 18 h. An advanced study evaluated the pharmacokinetic 
and pharmacodynamic effects of transdermally delivered 
insulin using novel CaCO3 nanoparticles in normal mice and 
those with diabetes 1. 
Iontophoresis, it is a technique that enhance the 
transdermal delivery of compounds through the skin via the 
application of a small electric current. one of the most 
advanced technologies that have been developed in the 20th 
century to overcome low skin permeability to insulin is 
iontophoresis. Iontophoresis is a technique used to enhance 
the transdermal delivery of compounds through the skin by 
the application of a small electric current. Using the 
processes of electro migration and electro-osmosis, 
iontophoresis increases the permeation of charged and 
neutral compounds. It offers the option of a programmed 
drug delivery technique that physically facilitates the 
transport of permeates across the skin1. 
Ultrasound/Sonophoresis, uses ultrasound and it has been 
shown to increase skin permeability to various low and high 
molecular weight drugs, including insulin. However, its 
therapeutic value is still being evaluated. Ultrasound has an 
ever-increasing role in the delivery of therapeutic agents, 
including genetic material, proteins, and chemotherapeutic 
agents. There is a tremendous corpus of literature on the use 
of ultrasound to enhance the permeability of the skin for 
transdermal drug delivery. Therapeutic levels of ultrasound 
(1–3 MHz, 1–3 W/cm2) have been used for years to drive 
small hydrophobic molecules, like steroids, into or through 
the skin. Absorption enhancers have sometimes been used 
to increase skin permeability further. However, no 
significant transport of protein was achieved until 10 years 
ago1. 
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Microneedles, offers a cost-effective, minimally invasive, 
and controllable approach to transdermal insulin delivery. It 
involves the creation of micronized channels in the skin, and 
therefore disturbs the stratum corneum barrier. Upon 
creation of the microchannels, interstitial fluid fills up the 
channels, resulting in hydrophilic pathways. Microneedles 
deliver the drug into the epidermis without causing any 
damage or disruption of nerve endings 10. Microneedles have 
been regarded as a healthy technology approach to be used 
either alone or with other enhancing techniques such as 
Electroporation and Iontophoresis, as well as with different 
drug carriers (lipid vesicles, micro- and nanoparticles) 8. As 
Microneedles inserted into the skin of human subjects are 
reported to be painless, microneedles are considered as a 
promising technology to deliver drugs into the skin 9,8.  
Microdermabrasion, is a method to increase skin 
permeability for transdermal drug delivery by damaging or 
removing skin’s outer layer, stratumcorneum. 
Microdermabrasion can increase skin permeability to 
deliver insulin 8,1. 
Characteristics of transdermal insulin drug delivery system 
are given below: 
i. It gives passive delivery of insulin. 
ii. Patch, cream, and spray forms can be used. 
 Iii. It requires a day to diffuse through skin and to have 
systemic effect. 
The advantages of transdermal delivery of insulin includes : 
1. Convenience   
2. Good patient compliance   
3. Prolonged therapy and   
4. Avoids liver’s first-pass metabolism and degradation in 
the gastrointestinal tract.  
The main drawback of the transdermal drug delivery is that 
insulin molecules are large enough to penetrate the skin at 
therapeutically useful rates. This requires the usage of 
Microneedles as said above as one of enhancing techniques 
available 8. 
Drawback of transdermal drug delivery is that insulin 
molecules are large enough to penetrate the skin at 
therapeutically useful rates. So nowadays microneedles are 
being fabricated with different sizes, shapes, and so forth to 
increase transdermal delivery. Various in vivo and in vitro 
studies have shown better results with solid microneedles. 
Needle arrays increase the transport by diffusion and 
iontophoresis and as drug carriers 5. 
3.6. Gene therapy: 
Gene therapy is the use of DNA as a pharmaceutical agent to 
treat disease. Fig. 8 illustrates gene therapy using an 
adenovirus vector. A new gene is inserted into a cell using an 
adenovirus. If the treatment is successful, the new gene will 
make functional protein to treat a disease [55]. To regulate 
insulin a gene called SHIP2 has been identified which 
provides a potential gene therapy target for the treatment of 
type 2 diabetes [56]. The first FDA-approved gene therapy 
experiment in the United States occurred in 1990, when 
Ashanti De Silva was treated for ADA-SCID10. 
3.8. Absorption enhancer: 
 and enzyme inhibitors  Certain compounds like bile salts, 
chelating  agents, long chain fatty acids and amphiphilic 
surfactants can be used as absorption enhancers( 
Eaimtrakarn et al,.2002,Aungst, 1994; Coudhari et al., 1994; 
Senel et al., 1997).These substances increase the para-
cellular transport either by increasing the fluidity of the 
membrane or by decreasing the viscosity of thick mucosal 
lining of the git and hence increase the absorption( Mahato 
et al.,2003).It was found that the bioavailability of insulin 
was enhanced to many times when it was formulated along 
with absorption enhancers like sodium glycholate ( 
Morishita et al.,1993).Mixed micellar systems of bile salts 
increase the  absorption of insulin by  increasing its  para-
cellular permeability( Lane et al,.2005).  As insulin gets 
rapidly degraded in git by intestinal enzymes like trypsin, 
chymotrypsin and elastase, inclusion of compounds which 
act as inhibitors to these enzymes may provide a viable 
enzymatic barrier for insulin delivery via oral 
route(.yamamoto etal., 1994, Carino, et al,. 1994).Substances 
like aprotinin (Morishita et al,.1990),bacitracin,soyabean 
trypsin inhibitor ,chick and duck ovomucoids (Agarwal et 
al,.2000) have shown to offer protection against these 
enzymes and thus increasing the bioavailability of  orally 
administered insulin( Yamamoto et al,1990) 2. 
4. INSULIN DEVICES 
Insulin infusion devices may be classified as two types such 
as open-loop and closed-loop systems.open-loop micropump 
insulin delivery device consist of a small, lightweight, 
portable insulin micropump and plastic tubing which 
connects the pump to a needle inserted under the skin. 
Insulin release patterns in them can be preprogrammed and 
initiated by timer or by the diabetic patient himself. This 
device demands a very careful monitoring of blood glucose 
level. Also the patients using these devices were reported to 
show high incidence of ketoacidosis. Implantable versions of 
open loop insulin infusion devices were also introduced. 
Chemically controlled closed loop insulin delivery devices 
work by alternative in the absence of an effective pancreatic 
activity. They are biocompatible and non-toxic. The 
biohybrid artificial pancreas is another type of insulin 
diffusion device, which is under research. These contain B-
cells enclosed within a semi permeable membrane, which is 
biocompatible.  The semi permeable membrane is 
permeable to glucose and insulin. Special has to be given to 
exclude immune cells in order to prevent rejection by the 
body11. 
 5. INSULIN PUMPS: 
Insulin pumps were developed to avoid repetitive 
subcutaneous injections. The pump itself is essentially. The 
insulin pump is an open-loop system that has two 
concurrent modes of insulin delivery:  
(1) Continuously through basal infusion and  
(2) Intermittently through bolus insulin delivery. Insulin 
replacement can be provided in a near physiologic fashion, 
integrating both lower basal insulin secretion and higher 
postprandial requirements. 
Insulin pumps have provided additional flexibility of 
modifying basal insulin replacement in response to circadian 
rhythms10. Moreover, it can be preprogrammed to decrease 
during exercise and increase during times of inactivity11. 
Studies conducted with improved versions of insulin such as 
insulin lispro, show that when used in external insulin 
pumps, it provides better glycemic control than buffered 
regular human insulin with a similar adverse event profile 
possibly due to rapid absorbtion13. The major advantages 
over multiple injections are a reduction of nightly instability 
and hypoglycemia and time flexibility. Patients poorly 
controlled under injections and/ or with recurrent 
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hypoglycemias thus represent the best candidates for 
therapy with pumps3,5. 
A basic problem with insulin pumps is the potential 
alteration of the administered insulin by motion, contact 
with pump surfaces and changes in temperature. Insulin 
forms aggregated macromolecules that have reduced insulin 
activity and tend to precipitate in the catheter, causing 
obstruction. Insulin must be buffered and treated with 
additives to increase viscosity, thereby improving its 
physical stability. The other drawback is of encapsulation by 
the dense fibrous tissue of the implant7. Early versions of 
insulin pumps were plagued by problems with fluid leakage 
into the system, short battery life, insulin blockage of the 
pump or catheter and tissue blockage of the peritoneal 
catheters and adhesions. Information on plasma glucose 
level is prerequisite for effective metabolic control by 
external insulin pumps as well as conventional 
subcutaneous injection. Therefore, there is a continuing 
need for self-regulated delivery systems, having the 
capability of adapting the rate of insulin release in response 
to changes in glucose concentration, in order to keep the 
blood glucose levels within the normal range. The attempt is 
to restore the feedback between blood glucose and insulin 
delivery6. 
Advantages of pump therapy 
        i. More physiologic  
ii. Less variable insulin absorption. 
       iii. Better match between insulin and food  
       iv. Greater lifestyle flexibility  
       v. Easier to travel - improved portability6 . 
CONCLUSION: 
The natural history of diabetes mellitus requires steady, 
precise and predictable insulin delivery, to preserve 
euglycemia. Too much or too little insulin and at an 
improper time can quickly cause an emergency Recent 
alternatives developed in insulin therapy have potential for 
reducing some of the negative aspects of current methods. 
Oral insulin in particular could prove to be promising 
alternative method, especially with nanotechnology allowing 
for several types of encapsulations to bypass the gastric 
acidic environment. Oral delivery offers the benefits of ease 
of administration by increasing the acceptance of patient, 
improved absorption rates, and mimicry of the normal route 
of insulin through the liver. Apart from few drawbacks, 
inhaled insulin is also a good achievement in the field of 
noninvasive delivery of insulin due to its good absorptive 
nature, fast onset of action, longer blood glucose lowering 
activity and also has a potential to treat postprandial 
hyperglycemia effectively when compared to traditionally 
administer subcutaneous route.  
From this review we have concluded that there is a need of 
developing noninvasive therapy of insulin for diabetes 
mellitus, as it has greater advantages than existing invasive 
therapy of insulin.  
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